These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 30341696)

  • 1. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
    Youdim MBH
    J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
    Youdim MB; Bakhle YS
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
    Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
    J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
    Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
    Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
    J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.
    Weinreb O; Mandel S; Bar-Am O; Amit T
    J Neural Transm (Vienna); 2011 Mar; 118(3):479-92. PubMed ID: 21360301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
    Youdim MB; Kupershmidt L; Amit T; Weinreb O
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
    Youdim MB; Lavie L
    Life Sci; 1994; 55(25-26):2077-82. PubMed ID: 7527888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
    Youdim MB
    Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.